MARKET

TECX

TECX

Tectonic Therapeutic Inc
NASDAQ
20.69
+0.79
+3.97%
After Hours: 20.69 0 0.00% 16:05 05/15 EDT
OPEN
20.22
PREV CLOSE
19.90
HIGH
21.31
LOW
19.52
VOLUME
136.26K
TURNOVER
--
52 WEEK HIGH
61.07
52 WEEK LOW
1.220
MARKET CAP
386.33M
P/E (TTM)
-5.4110
1D
5D
1M
3M
1Y
5Y
1D
Tectonic Therapeutic Is Maintained at Outperform by Mizuho
Dow Jones · 19h ago
Mizuho Maintains Outperform on Tectonic Therapeutic, Raises Price Target to $85
Benzinga · 19h ago
Tectonic Therapeutic price target raised to $85 from $51 at Mizuho
TipRanks · 22h ago
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)
TipRanks · 1d ago
Tectonic Therapeutic’s Strategic Advancements and Financial Efficiency Earn Buy Rating
TipRanks · 3d ago
Weekly Report: what happened at TECX last week (0505-0509)?
Weekly Report · 4d ago
Piper Sandler Remains a Buy on Tectonic Therapeutic (TECX)
TipRanks · 6d ago
Mizuho Securities Keeps Their Buy Rating on Tectonic Therapeutic (TECX)
TipRanks · 05/09 03:36
More
About TECX
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).

Webull offers Tectonic Therapeutic Inc stock information, including NASDAQ: TECX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TECX stock methods without spending real money on the virtual paper trading platform.